Login / Signup

Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma.

Lingxi JiangJiejie QinYu-Ting DaiShulin ZhaoQian ZhanPeng CuiLingjie RenXuelong WangRuihong ZhangChenxu GaoYanting ZhouShangli CaiGuoqiang WangWenchuan XieXiaomei TangMinmin ShiFangfang MaJia LiuTing WangChaofu WangMagali SvrcekArmelle Bardier-DupasJean François EmileLouis de MestierJean-Baptiste BachetRemy NicolleJerome CrosPierre Laurent-PuigMiaoyan WeiBin SongWei JingShiwei GuoKailian ZhengHui JiangHuan WangXiaxing DengHao ChenQiang TianShengyue WangXianjun YuGang JinTong YinHai FangSai-Juan ChenBaiyong Shen
Published in: Nature medicine (2024)
Adjuvant chemotherapy benefits patients with resected pancreatic ductal adenocarcinoma (PDAC), but the compromised physical state of post-operative patients can hinder compliance. Biomarkers that identify candidates for prompt adjuvant therapy are needed. In this prospective observational study, 1,171 patients with PDAC who underwent pancreatectomy were enrolled and extensively followed-up. Proteomic profiling of 191 patient samples unveiled clinically relevant functional protein modules. A proteomics-level prognostic risk model was established for PDAC, with its utility further validated using a publicly available external cohort. More importantly, through an interaction effect regression analysis leveraging both clinical and proteomic datasets, we discovered two biomarkers (NDUFB8 and CEMIP2), indicative of the overall sensitivity of patients with PDAC to adjuvant chemotherapy. The biomarkers were validated through immunohistochemistry on an internal cohort of 386 patients. Rigorous validation extended to two external multicentic cohorts-a French multicentric cohort (230 patients) and a cohort from two grade-A tertiary hospitals in China (466 patients)-enhancing the robustness and generalizability of our findings. Moreover, experimental validation through functional assays was conducted on PDAC cell lines and patient-derived organoids. In summary, our cohort-scale integration of clinical and proteomic data demonstrates the potential of proteomics-guided prognosis and biomarker-aided adjuvant chemotherapy for PDAC.
Keyphrases